CO2023012684A2 - Compuestos agonistas beta del receptor de la hormona tiroidea - Google Patents
Compuestos agonistas beta del receptor de la hormona tiroideaInfo
- Publication number
- CO2023012684A2 CO2023012684A2 CONC2023/0012684A CO2023012684A CO2023012684A2 CO 2023012684 A2 CO2023012684 A2 CO 2023012684A2 CO 2023012684 A CO2023012684 A CO 2023012684A CO 2023012684 A2 CO2023012684 A2 CO 2023012684A2
- Authority
- CO
- Colombia
- Prior art keywords
- thyroid hormone
- agonist compounds
- hormone receptor
- receptor beta
- beta
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 229940123876 Thyroid hormone receptor beta agonist Drugs 0.000 title 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 abstract 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000005495 thyroid hormone Substances 0.000 abstract 1
- 229940036555 thyroid hormone Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Se proporcionan en la presente descripción compuestos, preferentemente compuestos agonistas del receptor beta de la hormona tiroidea (THR beta), composiciones de estos, y métodos de su preparación, y métodos para agonizar el THR beta y métodos para tratar trastornos mejorados por la activación del THR beta.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163156227P | 2021-03-03 | 2021-03-03 | |
| PCT/US2022/018575 WO2022187403A1 (en) | 2021-03-03 | 2022-03-02 | Thyroid hormone receptor beta agonist compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2023012684A2 true CO2023012684A2 (es) | 2023-10-19 |
Family
ID=83154837
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2023/0012684A CO2023012684A2 (es) | 2021-03-03 | 2023-09-26 | Compuestos agonistas beta del receptor de la hormona tiroidea |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20240059682A1 (es) |
| EP (1) | EP4301357A1 (es) |
| JP (1) | JP2024510935A (es) |
| KR (1) | KR20230152095A (es) |
| CN (1) | CN117120051A (es) |
| AU (1) | AU2022228569A1 (es) |
| BR (1) | BR112023017612A2 (es) |
| CA (1) | CA3212130A1 (es) |
| CL (1) | CL2023002601A1 (es) |
| CO (1) | CO2023012684A2 (es) |
| IL (1) | IL305495A (es) |
| MX (1) | MX2023010324A (es) |
| PE (1) | PE20240097A1 (es) |
| WO (1) | WO2022187403A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114075173A (zh) * | 2020-08-19 | 2022-02-22 | 成都凡诺西生物医药科技有限公司 | 腈代三嗪类衍生物及其制备方法和应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH634306A5 (de) * | 1977-04-12 | 1983-01-31 | Ciba Geigy Ag | Benzimidazolderivate, verfahren zu ihrer herstellung und anthelmintische mittel enthaltend diese verbindungen als wirkstoffe. |
| CN105477636B (zh) * | 2015-10-16 | 2019-09-17 | 厦门大学 | 使用阿维菌素及其衍生物治疗代谢疾病的方法 |
| TW202220968A (zh) * | 2016-01-29 | 2022-06-01 | 美商維它藥物有限責任公司 | ＲＯＲ－γ調節劑 |
| TWI837169B (zh) * | 2018-08-24 | 2024-04-01 | 美商拓臻股份有限公司 | 甲狀腺素受體β促效劑化合物 |
| CN115215838A (zh) * | 2018-09-18 | 2022-10-21 | 拓臻股份有限公司 | 用于治疗特定白血病的化合物 |
| TWI840423B (zh) * | 2018-10-12 | 2024-05-01 | 美商拓臻股份有限公司 | 甲狀腺素受體β促效劑化合物 |
| CN111320609A (zh) * | 2018-12-13 | 2020-06-23 | 拓臻股份有限公司 | 一种THRβ受体激动剂化合物及其制备方法和用途 |
| MA55890A (fr) * | 2019-05-08 | 2022-03-16 | Aligos Therapeutics Inc | Modulateurs de thr-beta et leurs procédés d'utilisation |
-
2022
- 2022-03-02 AU AU2022228569A patent/AU2022228569A1/en active Pending
- 2022-03-02 EP EP22764006.7A patent/EP4301357A1/en active Pending
- 2022-03-02 IL IL305495A patent/IL305495A/en unknown
- 2022-03-02 PE PE2023002483A patent/PE20240097A1/es unknown
- 2022-03-02 CA CA3212130A patent/CA3212130A1/en active Pending
- 2022-03-02 WO PCT/US2022/018575 patent/WO2022187403A1/en active Application Filing
- 2022-03-02 JP JP2023553065A patent/JP2024510935A/ja active Pending
- 2022-03-02 MX MX2023010324A patent/MX2023010324A/es unknown
- 2022-03-02 KR KR1020237032893A patent/KR20230152095A/ko unknown
- 2022-03-02 BR BR112023017612A patent/BR112023017612A2/pt unknown
- 2022-03-02 US US18/548,650 patent/US20240059682A1/en active Pending
- 2022-03-02 CN CN202280027156.1A patent/CN117120051A/zh active Pending
-
2023
- 2023-09-01 CL CL2023002601A patent/CL2023002601A1/es unknown
- 2023-09-26 CO CONC2023/0012684A patent/CO2023012684A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL305495A (en) | 2023-10-01 |
| CN117120051A (zh) | 2023-11-24 |
| EP4301357A1 (en) | 2024-01-10 |
| PE20240097A1 (es) | 2024-01-18 |
| CL2023002601A1 (es) | 2024-03-22 |
| WO2022187403A1 (en) | 2022-09-09 |
| AU2022228569A1 (en) | 2023-10-12 |
| CA3212130A1 (en) | 2022-09-09 |
| MX2023010324A (es) | 2023-11-09 |
| BR112023017612A2 (pt) | 2023-12-05 |
| JP2024510935A (ja) | 2024-03-12 |
| US20240059682A1 (en) | 2024-02-22 |
| KR20230152095A (ko) | 2023-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020011562A (es) | Agonistas del receptor de la hormona tiroidea y usos de los mismos. | |
| CR20180594A (es) | Agonista del receptor de glucocorticoides e inmunoconjugados del mismo | |
| BR112021013824A2 (pt) | Receptores de antígeno quiméricos gprc5d e células que expressam os mesmos | |
| CL2021000343A1 (es) | Inhibidores peptídicos del receptor de interleucina 23 (divisional de la solicitud n° 201800128) | |
| CO2022010330A2 (es) | Dosificación de gamma-hidroxibutirato (ghb) | |
| CL2021001075A1 (es) | Agonista del receptor de glucocorticoides e inmunoconjugados de este solicitud divisional de 202001452) | |
| CO2020000056A2 (es) | Nuevos compuestos y composiciones farmacéuticas de los mismos para el tratamiento de la fibrosis | |
| PA8805801A1 (es) | Agonistas novedosos de los receptores de glucorticoides | |
| CO2023015484A2 (es) | Compuesto, composiciones y métodos para el tratamiento de trastornos | |
| CL2019001963A1 (es) | Método para tratar o mejorar trastornos metabólicos mediante el uso de agonistas del receptor glp-1 conjugados con antagonistas del receptor del péptido inhibidor gástrico (gipr). | |
| CL2019002255A1 (es) | 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas. | |
| CO2022006712A2 (es) | Inhibidores de las cinasas raf | |
| CO2023012684A2 (es) | Compuestos agonistas beta del receptor de la hormona tiroidea | |
| EA202190377A1 (ru) | Композиции ингибиторов cxcr4 и способы получения и применения | |
| CR20210607A (es) | Anticuerpos de receptor de péptido natriurético 1 y métodos de uso | |
| CL2021001818A1 (es) | Métodos y composiciones para el tratamiento del cáncer | |
| CL2021003273A1 (es) | Composición farmacéutica parenteral del agonista dual glp1/2 | |
| CO2020005919A2 (es) | Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas | |
| CL2008003802A1 (es) | Compuestos derivados de tioeteres c-21, agonistas del receptor de glucocorticoide; composicion farmaceutica; y uso para el tratamiento o profilaxis de una enfermedad o afeccion inmune, autoinmune o inflamatoria, tales como artritis reumatoide y esclerosis multiple. | |
| CL2022002395A1 (es) | Compuestos para su uso en afecciones inflamatorias | |
| CL2022003703A1 (es) | Compuestos antibióticos, métodos de fabricación de los mismos, composiciones farmacéuticas conteniendo los mismos y usos | |
| CO2023013500A2 (es) | Anticuerpos anti-cd19 y estructuras car-t | |
| CL2023001492A1 (es) | Anticuerpos anti-ly6g6d y métodos de uso. | |
| CR20110305A (es) | Péptidos antagonistas de crhr2 y usos de estos | |
| CL2021001944A1 (es) | Derivados de aminoácidos para el tratamiento de enfermedades inflamatorias |